Ann Arbor area business briefs: University Bank and Retirement Income Solutions - 2 days ago
University of Michigan experts in...

Letter: Previous letter renders several opinions without facts

Elburn Herald - 2 days ago
As testified in trial, while Fox...

100 hospitals with great neurosurgery and spine programs | 2014

Becker's Hospital Review - 1 week ago
based Mayo Clinic, allowing...

For those with ALS, specialized computers a godsend

Richmond Times-Dispatch - 4 weeks ago
“CMS extended this review until...

The (seemingly) best stuff from the Carmel International Film Festival.

Monterey County Weekly - 1 week ago
Hilary Swank plays a young woman...

Why Brittany Maynard's choice to die is not personal or private

Washington Post - 1 week ago
Already, her decision has...

Airstrikes in Syria target ISIS forces

The Spokesman Review - 1 month ago
Using a mix of manned aircraft –...

Cooler consumption = cooler planet

Press of Atlantic City - 4 weeks ago
Ahead of this week's summit,...

Ecclestone on US Rare Earths – Heading Them Off at the Pass?

InvestorIntel - 2 weeks ago
Portions of the extracted rare...

Dows Kim Ann Mink Recognized as a Leader in Promoting STEM Diversity

MFRTech (press release) - 3 weeks ago
Part of that expansion was the...

News via Google. See more news matching 'als expanded access'


Expanded Access

Bringing Research and Patients Together

Our Expanded Access platform is meant to do two things:

  1. Empower patients with access to new treatments that are in clinical research.
  2. Empower further research with clinical data from those patients.

For someone with a quick-killer disease, participating in clinical research may be the only way to access a new medicine that might help him live longer.  He may be willing to accept some uncertainty, considering the alternative.  So for patients, there’s a lot of overlap between treatment exploration and research.

But what about patients who cannot get into clinical trials?  Can they still take part in research and explore investigational treatment?

Yes, they can, but only through what are called Expanded Access programs (EAPs).  These are meant to include a much broader group of patients than traditional clinical trials, sometimes exclusively those patients who don’t meet clinical trial enrollment criteria or who otherwise cannot get into trials.

ALS-ETF is bringing a new kind of Expanded Access to the ALS community, to make a groundbreaking impact in the treatment landscape for patients as well as the research that’s powered by patient data.

Learn more about Expanded Access programs here.

Learn more about our research goals here.